Abstract
Novel spheroid-type tumor cell cultures directly isolated from patients’ tumors preserve tumor characteristics better than traditionally grown cell lines. However, such cultures are not generally used for high-throughput toxicity drug screens. In addition, the assays that are commonly used to assess drug-induced toxicity in such screens usually measure a proxy for cell viability such as mitochondrial activity or ATP-content per culture well, rather than actual cell death. This generates considerable assay-dependent differences in the measured toxicity values. To address this problem we developed a robust method that documents drug-induced toxicity on a per-cell, rather than on a per-well basis. The method involves automated drug dispensing followed by paired image- and FACS-based analysis of cell death and cell cycle changes. We show that the two methods generate toxicity data in 96-well format which are highly concordant. By contrast, the concordance of these methods with frequently used well-based assays was generally poor. The reported method can be implemented on standard automated microscopes and provides a low-cost approach for accurate and reproducible high-throughput toxicity screens in spheroid type cell cultures. Furthermore, the high versatility of both the imaging and FACS platforms allows straightforward adaptation of the high-throughput experimental setup to include fluorescence-based measurement of additional cell biological parameters.
Highlights
Developed tissue culture protocols allow the generation of patient-derived cell lines from several tumor types in a manner that preserves the genetic and phenotypic aspects of the original tumor [1,2]
We have previously reported on the isolation and characterization of a series of cancer stem cell (CSC)-enriched non-adherent spheroid cultures from human colorectal tumors
We used irinotecan treatment of two phenotypically distinct colonosphere cultures to develop a new toxicity assay for spheroid-type tumor cell cultures
Summary
Developed tissue culture protocols allow the generation of patient-derived cell lines from several tumor types in a manner that preserves the genetic and phenotypic aspects of the original tumor [1,2]. One obvious application of such cultures is to use them in drug screens aimed at identifying effective drugs or drug combinations for targeting specific tumor subtypes, or even individual tumors, contributing to the personalization of cancer care. This imposes an experimental challenge as traditional cytotoxicity assays have been developed and optimized for traditional adherent cell culture models. The most commonly used approach is to measure the per-well amount of some aspect of cellular metabolism or biomass
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.